主要文件

查看所有文档

C3350000

阿糖胞苷

Name: 阿糖胞苷
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

胞嘧啶 β-D-呋喃阿拉伯糖苷, (β-D-阿拉伯呋喃糖基)胞嘧啶, Ara-C, 胞嘧啶阿拉伯糖苷, 阿拉伯糖胞嘧啶, 阿糖胞嘧啶, 阿糖胞苷

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₉H₁₃N₃O₅

化学文摘社编号:

147-94-4

分子量:

243.22

UNSPSC Code:

41116107

NACRES:

NA.24

PubChem Substance ID:

329775037

MDL number:

MFCD00066487

Beilstein/REAXYS Number:

89175

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

cytarabine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O

InChI

1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1

InChI key

UHDGCWIWMRVCDJ-CCXZUQQUSA-N

Gene Information

human ... POLA1(5422), POLA2(23649), POLD1(5424), POLD2(5425), POLD3(10714), POLD4(57804), POLE(5426), POLE2(5427), POLE3(54107), PRIM1(5557), PRIM2(5558)

说明

General description

本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持，请访问现行药典网站。

Application

阿糖胞苷EP参考标准品的预期用途是欧洲药典规定的实验室测试。

Biochem/physiol Actions

阿糖胞苷复合到 DNA 中后，可通过与导致 DNA 断裂的拓扑异构酶 I 形成可裂解复合物而抑制 DNA 的复制，但不会抑制 RNA 的合成。抗白血病制剂。

Packaging

本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。

Other Notes

可能适用相应的销售限制。

Still not finding the right product?

Explore all of our products under 阿糖胞苷

pictograms

GHS08

signalword

Danger

hcodes

H340,H361fd

pcodes

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Muta. 1B - Repr. 2

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

H Yang et al.

Leukemia, 28(6), 1280-1288 (2013-11-26)

Blockade of immune checkpoints is emerging as a new form of anticancer therapy. We studied the expression of programmed death ligand 1 (PD-L1), PD-L2, programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) mRNA in CD34+ cells from

Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition.

M R Sapienza et al.

Leukemia, 28(8), 1606-1616 (2014-02-08)

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease of controversial origin recently recognized as a neoplasm deriving from plasmacytoid dendritic cells (pDCs). Nevertheless, it remains an orphan tumor with obscure biology and dismal prognosis. To better understand the

Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses.

Erinn S Gideons et al.

Proceedings of the National Academy of Sciences of the United States of America, 111(23), 8649-8654 (2014-06-10)

Ketamine is an NMDA receptor (NMDAR) antagonist that elicits rapid antidepressant responses in patients with treatment-resistant depression. However, ketamine can also produce psychotomimetic effects that limit its utility as an antidepressant, raising the question of whether the clinically tolerated NMDAR

查看所有相关文献

全球贸易项目编号

货号	GTIN
C3350000	04061833485743